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health behaviour characteristics, comorbidities and health-related
quality of life.
Results: Of 62,103 CCHS respondents, 4785 self-reported a diag-
nosis of type 2 diabetes. There were 1169 insulin users, of which
35% (n¼405) were defined as early insulin users. Younger (<60
years) versus older (60 years) survey participants (adjusted odds
ratio [aOR] 1.9, 95% CI 1.4e2.6) and those overweight (BMI
25.0e29.9 kg/m2) vs. normal or underweight (BMI 24.9 kg/m2)
(aOR 0.4, 95% CI 0.3e0.6) had the most significant association with
early use of insulin. Significant factors that were associated with
early insulin use were post-secondary vs. no secondary school
diploma (aOR 0.7, 95% CI 0.5e1.0), English versus a Non-English or
Non-French first official spoken language (aOR 0.4, 95% CI 0.2e0.8),
and former smoking versus never smoking status (aOR 0.7, 95% CI
0.5e0.9).
Conclusion: Age, weight, education, official language spoken and
smoking status, were associated with initiating insulin use within 1
year of a diagnosis of type 2 diabetes.
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Effect of Loyalty to a Pharmacy on Antidiabetes Drug Adherence
and Use of Guidelines-Recommended Drugs
RICHI DOSSA, JEAN-PIERRE GRÉGOIRE, SOPHIE LAUZIER,
LINE GUÉNETTE, CAROLINE SIROIS, JOCELYNE MOISAN
Québec, QC; Lévis, QC
Objectives: Among individuals newly treated with oral anti-
diabetes drugs (AD), to assess the effect of pharmacy loyalty on
adherence to AD and on the guidelines-recommended drugs: 1)
ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB); 2) lipid-
lowering drug use.
Methods: Using Quebec administrative databases we carried
out a cohort study of individuals aged 18 years who had
started an oral AD between 2000 and 2006 and who had 2
years of follow up. Individuals who had filled all their pre-
scriptions in the same pharmacy during the 1st year after oral
AD initiation were considered loyal. Adherence to AD treatment
(persistence and proportion of days covered 80%) and use of
an ACEi/ARB and of a lipid-lowering drug were measured in the
2nd year. Outcomes were assessed using multivariate logistic
regressions.
Results: Among 124,009 eligible individuals, 59.8% were loyal to
their pharmacy, 80.8% were persistent with their AD, 78.2% of
persisters were compliant with their AD, 64.1% used an ACEI/ARB
and 63.7% used a lipid-lowering drug. Loyal individuals were
more likely to be persistent (odds ratio: 1.13; 95% CI: 1.09e1.16),
to be compliant with their AD (1.22; 1.19e1.26), to use an ACEI/
ARB (1.17; 1.14e1.20) and to use a lipid-lowering drug (1.21;
1.18e1.24).
Conclusions: Pharmacy loyalty is associated with a better quality
of AD use. It might be due to the fact that pharmacists can better
play their role in optimizing their clients’ drug use for patients loyal
to their pharmacy as they can then rely on recorded drug use in-
formation that is comprehensive.
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Prevalence of and Risk Factors for Diabetes Mellitus Among
Persons with Active Tuberculosis in Manitoba: A Population-
Based Study
CARLA ENS*, ROBERT WANG, SOLIMAN GUIRGIS, MARGARET FAST,
ANITA MOORE, NANCY YU
Winnipeg, MB
Background: Manitoba continues to have incidence and preva-
lence rates of both TB and diabetes well above the national
average. Diabetes has been identified as a risk factor for mortality
(and morbidity) in persons with TB disease. TB screening and
treatment for LTBI, if diagnosed, are recommended for persons
with insulin-dependent diabetes. The objective of this study is to
evaluate the prevalence of and risk factors for diabetes at or before
TB disease.
Methods: A population-based retrospective analysis was used to
describe the co-existing conditions. All records of persons with TB
disease reported from 1995/96 to 2012/13 were linked to the dia-
betes cohort (CCDSS) of the same period. Those with a diabetes
diagnosis, which occurred in or before their TB diagnosis year, were
counted as co-existing diabetes. Descriptive statistics and logistic
regression were used to describe the risk factors of co-existing
diabetes.
Results: Two thousand one hundred seventy-one active TB cases
were reported in the study period. 290 (13.4%) TB cases had
diabetes at the time of their TB diagnosis. Adjusted regression
analysis revealed that age and ethnicity/origin were associated
with co-existing diabetes. Using age 29 years as reference, the
risk of having co-existing diabetes was 13.4 (6.4e28.0), 37.1
(17.8e77.2), and 38.7 (18.4e81.2) times higher for aged 30e44,
45e59 and 60 years group, respectively. First Nation and
foreign-born persons had an increased risk of having co-existing
diabetes.
Conclusion: The results of this study support TB screening and co-
morbidity management in the populations (FN and foreign born)
with high burden of both diabetes and TB.
205
The Incidence of Drug-Induced Diabetes in Patients Taking
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ERIN DAVIS, MEGAN SNOW, HILARY PRICE, TERRI GENGE,
KRISTINA MEYERS, KELLY HATCH, JOHN-MICHAEL GAMBLE
St. John’s, NL; London, ON
Purpose: To conduct an overview of systematic reviewsmeasuring
the incidence of drug-induced diabetes in patients taking HMG-
CoA reductase inhibitors (statins), beta-adrenergic blockers (BBs),
calcium channel blockers (CCBs), thiazide diuretics and niacin.
Methods: Using a comprehensive search strategy, 2 independent
reviewers screened citations from several electronic databases.
Reference lists were hand searched. Systematic reviews of ran-
domized controlled trials were eligible for inclusion. The primary
outcome was the incidence of drug-induced diabetes. Secondary
outcomes included major adverse cardiac events, fatal and non-
fatal myocardial infarction and stroke, cardiovascular mortality and
all-cause mortality. The methodological quality was assessed using
the “assessment of multiple systematic reviews” (AMSTAR)
checklist.
Results: Nineteen systematic reviews met the pre-specified
criteria for inclusion. The mean (SD) AMSTAR score was 4.8 (2.8)
out of 11. 6/9 meta-analyses comparing statins vs. placebo or con-
trol demonstrated a statistically significant increase in the risk of
diabetes (relative risks [RR] ranged from 1.09e1.18). Pooled esti-
mates for secondary outcomes demonstrated statistically signifi-
cant reductions in cardiovascular outcomes for statins. Multiple
pooled estimates for drug-induced diabetes were reported for BBs
(12 estimates, RR ranged from 0.79e1.46), diuretic (12 estimates,
RR ranged from 0.57e1.59) and 4/6 CCB (9 estimates, RR ranged
from 0.75e1.27) reviews, as there were several active comparator
groups.
Conclusions: Statin meta-analyses suggest there is an increased
risk of diabetes associated with statin use; however, the cardio-
vascular benefits remain statistically and clinically significant. BBs,
CCBs and thiazides do not appear to consistently increase the risk of
diabetes, albeit the results vary by comparator.
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